Citius Pharmaceuticals Stock Net Income

CTXR Stock  USD 0.90  0.08  9.76%   
Citius Pharmaceuticals fundamentals help investors to digest information that contributes to Citius Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Citius Stock. The fundamental analysis module provides a way to measure Citius Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Citius Pharmaceuticals stock.
As of 03/29/2024, Net Loss is likely to grow to about (27.8 M). In addition to that, Net Loss is likely to grow to about (27.8 M).
  
This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

Citius Net Income Analysis

Citius Pharmaceuticals' Net income is the profit of a company for the reporting period, which is derived after taking revenues and gains and subtracting all expenses and losses. Net income is one of the most-watched numbers by money managers as well as individual investors.

Citius Pharmaceuticals Net Income

(27.82 Million)

Net Income

 = 

(Rev + Gain)

-

(Exp + Loss)

More About Net Income | All Equity Analysis

Current Citius Pharmaceuticals Net Income

    
  (32.54 M)  
Most of Citius Pharmaceuticals' fundamental indicators, such as Net Income, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Citius Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
Competition

Citius Accumulated Other Comprehensive Income

Accumulated Other Comprehensive Income

(6,337.26)

At this time, Citius Pharmaceuticals' Accumulated Other Comprehensive Income is relatively stable compared to the past year.
Based on the recorded statements, Citius Pharmaceuticals reported net income of (32.54 Million). This is 109.54% lower than that of the Pharmaceuticals sector and 146.46% lower than that of the Health Care industry. The net income for all United States stocks is 105.7% higher than that of the company.

Citius Net Income Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Citius Pharmaceuticals' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Citius Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Citius Pharmaceuticals by comparing valuation metrics of similar companies.
Citius Pharmaceuticals is currently under evaluation in net income category among related companies.

Citius Pharmaceuticals Institutional Holders

Institutional Holdings refers to the ownership stake in Citius Pharmaceuticals that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Citius Pharmaceuticals' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Citius Pharmaceuticals' value.
Shares
Goldman Sachs Group Inc2023-12-31
185.1 K
Inspire Advisors, Llc2023-12-31
182.7 K
Bank Of America Corp2023-12-31
180.6 K
Barclays Plc2023-12-31
168.8 K
Key Bridge Compliance Llc2023-09-30
154.1 K
Rhumbline Advisers2023-12-31
150.1 K
Susquehanna International Group, Llp2023-12-31
141 K
Ubs Group Ag2023-12-31
137.5 K
Arkadios Wealth Advisors2023-12-31
100 K
Blackrock Inc2023-12-31
8.5 M
Vanguard Group Inc2023-12-31
6.9 M

Citius Fundamentals

About Citius Pharmaceuticals Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Citius Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Citius Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Citius Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Last ReportedProjected for 2024
Net Loss-29.3 M-27.8 M
Net Loss-29.3 M-27.8 M
Net Loss-30.3 M-28.8 M
Net Income Per E B T 0.92  0.81 

Pair Trading with Citius Pharmaceuticals

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Citius Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Citius Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.
The ability to find closely correlated positions to Citius Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Citius Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Citius Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Citius Pharmaceuticals to buy it.
The correlation of Citius Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Citius Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Citius Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Citius Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
When determining whether Citius Pharmaceuticals is a strong investment it is important to analyze Citius Pharmaceuticals' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Citius Pharmaceuticals' future performance. For an informed investment choice regarding Citius Stock, refer to the following important reports:
Check out Citius Pharmaceuticals Piotroski F Score and Citius Pharmaceuticals Altman Z Score analysis.
To learn how to invest in Citius Stock, please use our How to Invest in Citius Pharmaceuticals guide.
You can also try the Instant Ratings module to determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance.

Complementary Tools for Citius Stock analysis

When running Citius Pharmaceuticals' price analysis, check to measure Citius Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Citius Pharmaceuticals is operating at the current time. Most of Citius Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Citius Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Citius Pharmaceuticals' price. Additionally, you may evaluate how the addition of Citius Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Portfolio Dashboard
Portfolio dashboard that provides centralized access to all your investments
Watchlist Optimization
Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm
Content Syndication
Quickly integrate customizable finance content to your own investment portal
Portfolio Backtesting
Avoid under-diversification and over-optimization by backtesting your portfolios
Sign In To Macroaxis
Sign in to explore Macroaxis' wealth optimization platform and fintech modules
Investing Opportunities
Build portfolios using our predefined set of ideas and optimize them against your investing preferences
Price Ceiling Movement
Calculate and plot Price Ceiling Movement for different equity instruments
Performance Analysis
Check effects of mean-variance optimization against your current asset allocation
Is Citius Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Citius Pharmaceuticals. If investors know Citius will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Citius Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(0.26)
Return On Assets
(0.23)
Return On Equity
(0.41)
The market value of Citius Pharmaceuticals is measured differently than its book value, which is the value of Citius that is recorded on the company's balance sheet. Investors also form their own opinion of Citius Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Citius Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Citius Pharmaceuticals' market value can be influenced by many factors that don't directly affect Citius Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Citius Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Citius Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Citius Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.